PharmEnable Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 23

PharmEnable Therapeutics General Information

Description

Developer of a molecule drug designed to replicate the specificity of biologics in the form of small molecules. The company uses a unique and diverse virtual compound library in conjunction with computational screening programs to identify novel active chemical starting points against the most challenging biological targets, enabling the medical community to develop medicines such as a novel antibacterial agent or cancer treatment.

Contact Information

Formerly Known As
PharmEnable
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Compass House, Vision Park
  • Histon
  • Cambridge CB24 9AD
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Compass House, Vision Park
  • Histon
  • Cambridge CB24 9AD
  • England, United Kingdom

PharmEnable Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PharmEnable Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC Completed Generating Revenue
6. Accelerator/Incubator 01-Jan-2024 Completed Generating Revenue
5. Later Stage VC (Series A) 20-Jul-2023 Completed Generating Revenue
4. Seed Round 28-Apr-2020 Completed Generating Revenue
3. Accelerator/Incubator 10-Oct-2017 Completed Startup
2. Accelerator/Incubator 01-Jan-2017 Completed Startup
1. University Spin-Out 17-Oct-2016 Completed Startup
To view PharmEnable Therapeutics’s complete valuation and funding history, request access »

PharmEnable Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A2
Series A
Ordinary 927,083 $0.000013 $2.56 $2.56 1x $2.56 28.55%
To view PharmEnable Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

PharmEnable Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a molecule drug designed to replicate the specificity of biologics in the form of small molecules. The comp
Drug Discovery
Cambridge, United Kingdom
13 As of 2026

Manchester, United Kingdom
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

PharmEnable Therapeutics Competitors (2)

One of PharmEnable Therapeutics’s 2 competitors is Biorelate, a Venture Capital-Backed company based in Manchester, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biorelate Venture Capital-Backed Manchester, United Kingdom
BioSymetrics Formerly VC-backed New York, NY
You’re viewing 2 of 2 competitors. Get the full list »

PharmEnable Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PharmEnable Therapeutics Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioIndustry Association Accelerator/Incubator
Arrowfield Capital Angel Group Minority
EMV Capital Venture Capital Minority
Heyford Trust Corporation Minority
Meltwind Advisory Venture Capital Minority
You’re viewing 5 of 23 investors. Get the full list »

PharmEnable Therapeutics FAQs

  • When was PharmEnable Therapeutics founded?

    PharmEnable Therapeutics was founded in 2016.

  • Where is PharmEnable Therapeutics headquartered?

    PharmEnable Therapeutics is headquartered in Cambridge, United Kingdom.

  • What is the size of PharmEnable Therapeutics?

    PharmEnable Therapeutics has 13 total employees.

  • What industry is PharmEnable Therapeutics in?

    PharmEnable Therapeutics’s primary industry is Drug Discovery.

  • Is PharmEnable Therapeutics a private or public company?

    PharmEnable Therapeutics is a Private company.

  • What is PharmEnable Therapeutics’s current revenue?

    The current revenue for PharmEnable Therapeutics is .

  • How much funding has PharmEnable Therapeutics raised over time?

    PharmEnable Therapeutics has raised $10.2M.

  • Who are PharmEnable Therapeutics’s investors?

    BioIndustry Association, Arrowfield Capital, EMV Capital, Heyford Trust, and Meltwind Advisory are 5 of 23 investors who have invested in PharmEnable Therapeutics.

  • Who are PharmEnable Therapeutics’s competitors?

    Biorelate and BioSymetrics are competitors of PharmEnable Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process